赛诺菲与再生元的Dupixent达成关键终点,获FDA优先审查接受

投资观察
Nov 07

11月7日 - 赛诺菲公司:赛诺菲与再生元的Dupixent关键研究满足所有主要和次要终点,减少了过敏性真菌性鼻窦炎的症状和体征;申请已被FDA接受为优先审查。三期研究数据显示,Dupixent减少了鼻部症状和体征。该药物已获得美国FDA的优先审查,目标决定日期为2026年2月28日。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10